Modality
Multispecific
MOA
AHRant
Target
FXIa
Pathway
Neuroinflam
Prostate Ca
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
~Mar 2017
→ ~Jun 2018
Phase 2
~Sep 2018
→ ~Dec 2019
Phase 3
Mar 2020
Phase 3Current
NCT07135024
427 pts·Prostate Ca
2020-03→TBD·Completed
427 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P3
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07135024 | Phase 3 | Prostate Ca | Completed | 427 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Elratapinarof | Halozyme | Phase 2 | C5 |